Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB001158 +/- Pembrolizumab in Advanced Solid Tumors
NCT02903914Phase 1Completed
- Sponsor
- Incyte
- Start
- Sep 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of numidargistat in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 7 more (8 arms), sponsored by Incyte. Primary endpoint: Treatment-emergent Adverse Events up to 3.5 years. Started Sep 2016; status: completed.
02
Drugs
numidargistat
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02903914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903914.